NMD3

Summary

NMD3 (NMD3 ribosome export adaptor, HGNC:24250) is a protein-coding gene on chromosome 3q26.1, encoding 60S ribosomal export protein NMD3 (Q96D46). Acts as an adapter for the XPO1/CRM1-mediated export of the 60S ribosomal subunit. It is a common-essential gene (DepMap: required in 99.1% of cancer cell lines).

Ribosomal 40S and 60S subunits associate in the nucleolus and are exported to the cytoplasm. The protein encoded by this gene is involved in the passage of the 60S subunit through the nuclear pore complex and into the cytoplasm. Several transcript variants exist for this gene, but the full-length natures of only two have been described to date.

Source: NCBI Gene 51068 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 107 total
• Cancer dependency (DepMap): dependent in 99.1% of screened cell lines (common-essential)
• MANE Select transcript: NM_015938

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24250
Approved symbol	NMD3
Name	NMD3 ribosome export adaptor
Location	3q26.1
Locus type	gene with protein product
Status	Approved
Aliases	CGI-07
Ensembl gene	ENSG00000169251
Ensembl biotype	protein_coding
OMIM	611021
Entrez	51068

Gene structure

Transcript identifiers

Ensembl transcripts: 27 — 25 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000351193, ENST00000460469, ENST00000460503, ENST00000463518, ENST00000468606, ENST00000472947, ENST00000473909, ENST00000476237, ENST00000478160, ENST00000493066, ENST00000878752, ENST00000878753, ENST00000878754, ENST00000878755, ENST00000878756, ENST00000878757, ENST00000878758, ENST00000878759, ENST00000878760, ENST00000917141, ENST00000917142, ENST00000945532, ENST00000945533, ENST00000945534, ENST00000945535, ENST00000945536, ENST00000945537

RefSeq mRNA: 2 — MANE Select: NM_015938 NM_001320227, NM_015938

CCDS: CCDS3194, CCDS82870

Canonical transcript exons

ENST00000351193 — 16 exons

Exon	Start	End
ENSE00001156866	161241046	161241163
ENSE00001167635	161238730	161238826
ENSE00001191920	161250256	161250326
ENSE00001191924	161249454	161249560
ENSE00001191928	161247258	161247330
ENSE00001191931	161246336	161246448
ENSE00001191935	161242508	161242653
ENSE00001867144	161250780	161252307
ENSE00001901424	161221311	161221409
ENSE00002328297	161235122	161235212
ENSE00003491779	161224930	161225064
ENSE00003603326	161221994	161222057
ENSE00003643985	161227247	161227343
ENSE00003646777	161233399	161233479
ENSE00003787073	161234727	161234855
ENSE00003789249	161238113	161238191

Expression profiles

Bgee: expression breadth ubiquitous, 280 present calls, max score 98.40.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 41.8797 / max 517.2459, expressed in 1812 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
39604	39.2042	1812
39605	0.8955	385
203004	0.8200	343
39602	0.4901	306
39603	0.4699	254

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	98.40	gold quality
germinal epithelium of ovary	UBERON:0001304	97.44	gold quality
upper leg skin	UBERON:0004262	96.77	gold quality
skin of hip	UBERON:0001554	96.68	gold quality
parotid gland	UBERON:0001831	96.59	gold quality
secondary oocyte	CL:0000655	96.50	gold quality
amniotic fluid	UBERON:0000173	96.41	gold quality
parietal pleura	UBERON:0002400	96.37	gold quality
visceral pleura	UBERON:0002401	96.33	gold quality
gingival epithelium	UBERON:0001949	96.31	gold quality
tibia	UBERON:0000979	96.30	gold quality
mammary duct	UBERON:0001765	96.14	gold quality
islet of Langerhans	UBERON:0000006	95.78	gold quality
heart right ventricle	UBERON:0002080	95.71	gold quality
calcaneal tendon	UBERON:0003701	95.68	gold quality
gingiva	UBERON:0001828	95.53	gold quality
oocyte	CL:0000023	95.22	gold quality
vena cava	UBERON:0004087	95.14	gold quality
cardia of stomach	UBERON:0001162	95.11	gold quality
pleura	UBERON:0000977	95.00	gold quality
cartilage tissue	UBERON:0002418	94.89	gold quality
pylorus	UBERON:0001166	94.88	gold quality
synovial joint	UBERON:0002217	94.64	gold quality
epithelium of nasopharynx	UBERON:0001951	94.59	gold quality
cauda epididymis	UBERON:0004360	94.55	gold quality
saphenous vein	UBERON:0007318	94.43	gold quality
superficial temporal artery	UBERON:0001614	94.39	gold quality
mucosa of paranasal sinus	UBERON:0005030	94.38	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	94.11	gold quality
tendon	UBERON:0000043	93.77	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.60
E-ENAD-17	no	1762.64
E-MTAB-10137	no	103.03

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

80 targeting NMD3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3162-3P	100.00	65.37	363
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-4320	99.75	65.80	793
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-1283	99.69	72.42	3009

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 99.1% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 4)

• contains a CRM-1-dependent leucine-rich nuclear export signal and a complex, dispersed nuclear localization signal (NMD3) (PMID:12773398)
• The CRM1 and NMD3 have complex functions in pathways that couple rRNA synthetic and processing engines and that the rRNA synthesis rate may be adjusted according to proficiency in rRNA processing and export. (PMID:23782956)
• The presence of the rs34016896 allele in the NMD3 gene may contribute to the development of synucleinopathies. (PMID:29564728)
• The recessive and overdominant model of NMD3 rs34016896 was associated with cognitive impairment in Parkinson’s disease patients. (PMID:31937261)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	nmd3	ENSDARG00000015676
mus_musculus	Nmd3	ENSMUSG00000027787
rattus_norvegicus	Nmd3	ENSRNOG00000009310
drosophila_melanogaster	Nmd3	FBGN0023542
caenorhabditis_elegans	T25G3.3	WBGENE00012030

Protein

Protein identifiers

60S ribosomal export protein NMD3 — Q96D46 (reviewed: Q96D46)

All UniProt accessions (6): C9IY70, C9IZW9, C9J0B9, C9JA08, C9K0C2, Q96D46

UniProt curated annotations — full annotation on UniProt →

Function. Acts as an adapter for the XPO1/CRM1-mediated export of the 60S ribosomal subunit.

Subunit / interactions. Found in a 60S ribosomal subunit export complex with RAN and XPO1. Interacts with XPO1. Associates with pre-60S ribosomal particles.

Subcellular location. Cytoplasm. Nucleus.

Similarity. Belongs to the NMD3 family.

RefSeq proteins (2): NP_001307156, NP_057022* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007064	Nmd3_N	Domain
IPR039768	Nmd3	Family
IPR048898	OB_NMD3	Domain
IPR048899	NMD_SH3	Domain

Pfam: PF04981, PF21192, PF21193

UniProt features (16 total): mutagenesis site 5, modified residue 5, short sequence motif 2, chain 1, region of interest 1, sequence conflict 1, sequence variant 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
6LQM	ELECTRON MICROSCOPY	3.09
6LSR	ELECTRON MICROSCOPY	3.13
6LU8	ELECTRON MICROSCOPY	3.13

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96D46-F1	86.72	0.52

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 1, 258, 433, 468, 470

Mutagenesis-validated functional residues (5):

Position	Phenotype
405	reduces accumulation in the nucleus. loss of nucleolar localization; when associated with a-406.
406	reduces accumulation in the nucleus. loss of nucleolar localization; when associated with a-405.
480	reduces nuclear export.
484	reduces nuclear export.
487	reduces nuclear export.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 154 (showing top): MODULE_97, GOBP_RIBOSOME_BIOGENESIS, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GOZGIT_ESR1_TARGETS_DN, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION, MODULE_182, chr3q26, GOBP_NUCLEAR_TRANSPORT, GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION_TO_NUCLEUS, VERNELL_RETINOBLASTOMA_PATHWAY_DN, DODD_NASOPHARYNGEAL_CARCINOMA_UP, WANG_TARGETS_OF_MLL_CBP_FUSION_DN, GOBP_PROTEIN_LOCALIZATION_TO_ORGANELLE

GO Biological Process (4): ribosomal large subunit export from nucleus (GO:0000055), protein transport (GO:0015031), positive regulation of RNA biosynthetic process (GO:1902680), positive regulation of protein localization to nucleolus (GO:1904751)

GO Molecular Function (3): RNA binding (GO:0003723), protein-macromolecule adaptor activity (GO:0030674), ribosomal large subunit binding (GO:0043023)

GO Cellular Component (5): nucleus (GO:0005634), nucleoplasm (GO:0005654), nucleolus (GO:0005730), cytoplasm (GO:0005737), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
nuclear lumen	2
ribosomal subunit export from nucleus	1
transport	1
intracellular protein localization	1
establishment of protein localization	1
positive regulation of macromolecule biosynthetic process	1
RNA biosynthetic process	1
positive regulation of RNA metabolic process	1
regulation of RNA biosynthetic process	1
positive regulation of protein localization to nucleus	1
protein localization to nucleolus	1
regulation of protein localization to nucleolus	1
nucleic acid binding	1
protein binding	1
molecular adaptor activity	1
ribosome binding	1
intracellular membrane-bounded organelle	1
intracellular membraneless organelle	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

2540 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NMD3	XPO1	O14980	990
NMD3	LSG1	Q9H089	872
NMD3	RSL24D1	Q9UHA3	843
NMD3	GNL2	Q13823	842
NMD3	NSA2	O95478	840
NMD3	MRTO4	Q9UKD2	811
NMD3	MDN1	Q9NU22	744
NMD3	RRP12	Q5JTH9	744
NMD3	RPL10	P27635	737
NMD3	GTPBP4	Q9BZE4	727
NMD3	LTV1	Q96GA3	725
NMD3	RPF2	Q9H7B2	725
NMD3	RIOK2	Q9BVS4	723
NMD3	WDR12	Q9GZL7	708
NMD3	WDR74	Q6RFH5	702

IntAct

74 interactions, top by confidence:

A	B	Type	Score
GCLC	GCLM	psi-mi:“MI:0914”(association)	0.790
ATF2	BACH1	psi-mi:“MI:0914”(association)	0.780
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
NMD3	LNX2	psi-mi:“MI:0915”(physical association)	0.550
ST8SIA1	POTEF	psi-mi:“MI:0914”(association)	0.530
NMD3	POTEF	psi-mi:“MI:0914”(association)	0.530
KLHDC2	PFDN1	psi-mi:“MI:0914”(association)	0.530
SLC31A1	C2orf72	psi-mi:“MI:0914”(association)	0.530
SGSH	FBXO21	psi-mi:“MI:0914”(association)	0.530
DTX3	ITSN1	psi-mi:“MI:0914”(association)	0.530
rep	NKRF	psi-mi:“MI:0914”(association)	0.500
NMD3	CSNK2A1	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
XPO1	NMD3	psi-mi:“MI:0915”(physical association)	0.400
NMD3	HAT1	psi-mi:“MI:0915”(physical association)	0.400
JUN	TPM3	psi-mi:“MI:0914”(association)	0.350
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
GPD1	IDH3B	psi-mi:“MI:0914”(association)	0.350
DTX3	NDUFS6	psi-mi:“MI:0914”(association)	0.350
CPEB1	APBA3	psi-mi:“MI:0914”(association)	0.350
SFTA2	SEPTIN2	psi-mi:“MI:0914”(association)	0.350
GSTT2B	SIRT2	psi-mi:“MI:0914”(association)	0.350
	SYNGR1	psi-mi:“MI:0914”(association)	0.350
SLX4	DDX39A	psi-mi:“MI:0914”(association)	0.350
OTUD4	KRT36	psi-mi:“MI:0914”(association)	0.350
RMC1	ANXA2P2	psi-mi:“MI:0914”(association)	0.350

BioGRID (152): NMD3 (Affinity Capture-MS), NMD3 (Affinity Capture-MS), NMD3 (Affinity Capture-MS), ARHGAP1 (Co-fractionation), CNBP (Co-fractionation), DIS3 (Co-fractionation), FLNA (Co-fractionation), GDI1 (Co-fractionation), GFPT1 (Co-fractionation), IMPDH2 (Co-fractionation), LSM7 (Co-fractionation), NMD3 (Co-fractionation), NMD3 (Co-fractionation), NMD3 (Co-fractionation), NMD3 (Co-fractionation)

ESM2 similar proteins: A2X0Q3, A2X8Q3, A3KMV5, A7YW45, O14744, O23979, O44081, O48556, O77814, O80585, O82597, O82793, P00366, P00367, P10860, P21216, P22314, P26443, P27793, P42174, P42898, P49448, P57720, P82264, Q02053, Q0DYB1, Q29504, Q43187, Q4R5M3, Q5BLF0, Q5I598, Q5R698, Q5RC82, Q5U300, Q60HE5, Q64HZ8, Q64HZ9, Q64I00, Q64I01, Q6GNS3

Diamond homologs: G0S488, P38861, Q08DS5, Q09817, Q55BF2, Q5BLF0, Q5RC82, Q6GNS3, Q6P2Z6, Q96D46, Q99L48

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

107 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	83
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2267 predictions. Top by Δscore:

Variant	Effect	Δscore
3:161221410:G:GG	donor_gain	1.0000
3:161222058:G:GG	donor_gain	1.0000
3:161224928:A:AG	acceptor_gain	1.0000
3:161224929:G:GG	acceptor_gain	1.0000
3:161227243:TTAG:T	acceptor_loss	1.0000
3:161227245:A:T	acceptor_loss	1.0000
3:161227246:GGT:G	acceptor_gain	1.0000
3:161227339:GTAAG:G	donor_gain	1.0000
3:161227342:AGGT:A	donor_loss	1.0000
3:161233476:AGAGG:A	donor_loss	1.0000
3:161233477:GAG:G	donor_gain	1.0000
3:161233478:AGGT:A	donor_loss	1.0000
3:161233479:GGT:G	donor_loss	1.0000
3:161233481:T:G	donor_loss	1.0000
3:161234876:G:GG	donor_gain	1.0000
3:161238110:A:AG	acceptor_gain	1.0000
3:161238110:AAGAT:A	acceptor_gain	1.0000
3:161238111:A:G	acceptor_gain	1.0000
3:161238111:AGAT:A	acceptor_gain	1.0000
3:161238112:G:GG	acceptor_gain	1.0000
3:161238112:GATG:G	acceptor_gain	1.0000
3:161241069:A:AG	acceptor_gain	1.0000
3:161241070:A:G	acceptor_gain	1.0000
3:161241071:AACT:A	acceptor_gain	1.0000
3:161241074:T:TA	acceptor_gain	1.0000
3:161242501:T:G	acceptor_gain	1.0000
3:161242506:A:AG	acceptor_gain	1.0000
3:161242506:AGT:A	acceptor_gain	1.0000
3:161242507:G:GA	acceptor_gain	1.0000
3:161242507:GT:G	acceptor_gain	1.0000

AlphaMissense

3365 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:161234848:G:T	R160M	1.000
3:161249505:T:A	W419R	1.000
3:161249505:T:C	W419R	1.000
3:161224979:T:C	C32R	0.999
3:161225048:T:A	C55S	0.999
3:161225048:T:C	C55R	0.999
3:161225049:G:A	C55Y	0.999
3:161225049:G:C	C55S	0.999
3:161225050:C:G	C55W	0.999
3:161227300:T:C	L78P	0.999
3:161233420:T:C	F100L	0.999
3:161233422:T:A	F100L	0.999
3:161233422:T:G	F100L	0.999
3:161234790:T:A	C141S	0.999
3:161234790:T:C	C141R	0.999
3:161234791:G:A	C141Y	0.999
3:161234791:G:C	C141S	0.999
3:161234799:T:A	C144S	0.999
3:161234799:T:C	C144R	0.999
3:161234800:G:C	C144S	0.999
3:161234826:T:A	W153R	0.999
3:161234826:T:C	W153R	0.999
3:161234848:G:C	R160T	0.999
3:161234849:G:C	R160S	0.999
3:161234849:G:T	R160S	0.999
3:161238115:G:C	G194R	0.999
3:161238116:G:A	G194D	0.999
3:161241056:T:A	V255D	0.999
3:161241114:T:G	C274W	0.999
3:161246447:G:A	G377R	0.999

dbSNP variants (sampled 300 via entrez): RS1000066568 (3:161221700 T>C,G), RS1000097307 (3:161228035 G>A), RS1000183326 (3:161248214 G>A), RS1000351003 (3:161240484 A>C,G), RS1000371237 (3:161240845 T>G), RS1000507644 (3:161249688 T>C), RS1000553891 (3:161221733 G>A,C), RS1000641739 (3:161249321 C>G,T), RS1000762809 (3:161226412 A>C), RS1000820552 (3:161235386 T>C), RS1000866184 (3:161235391 A>T), RS1000871169 (3:161235023 GAAAA>G,GAAA), RS1000918271 (3:161235031 A>G), RS1000977981 (3:161242731 T>A,C), RS1001220063 (3:161246817 T>C)

Disease associations

OMIM: gene MIM:611021 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST003262_485	Post bronchodilator FEV1	8.000000e-07
GCST003264_1101	Post bronchodilator FEV1/FVC ratio	4.000000e-06
GCST006102_15	Interleukin-10 levels	2.000000e-06
GCST007565_165	Morning person	3.000000e-15
GCST007565_43	Morning person	2.000000e-14
GCST007576_339	Chronotype	3.000000e-15

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004314	forced expiratory volume
EFO:0004713	FEV/FVC ratio
EFO:0004750	interleukin 10 measurement
EFO:0008328	chronotype measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases activity, affects cotreatment, increases abundance, increases expression, decreases expression	3
Hydrogen Peroxide	affects expression, increases expression	3
Air Pollutants	decreases expression, increases abundance	2
Arsenic	affects expression, affects cotreatment, increases abundance, increases expression	2
Tobacco Smoke Pollution	increases expression	2
Valproic Acid	affects cotreatment, increases expression, decreases expression	2
Cadmium Chloride	increases abundance, increases expression, decreases expression	2
FR900359	affects phosphorylation	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases methylation	1
beta-lapachone	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
potassium chromate(VI)	increases expression	1
beta-methylcholine	affects expression	1
K 7174	increases expression	1
ICG 001	decreases expression	1
abrine	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Leflunomide	increases expression	1
Cadmium	increases abundance, increases expression	1
Caffeine	decreases phosphorylation	1
Cisplatin	affects cotreatment, decreases expression	1
Coal	increases abundance, decreases expression	1
Doxorubicin	increases expression	1
Hydralazine	affects cotreatment, increases expression	1
Ivermectin	decreases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer